Shares of Cambrex Corp. (NYSE:CBM) reached a new 52-week high during trading on Wednesday . The stock traded as high as $59.19 and last traded at $58.96, with a volume of 126,981 shares trading hands. The stock had previously closed at $57.88.

Separately, Zacks Investment Research downgraded shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $58.20.

The stock has a 50 day moving average price of $51.91 and a 200 day moving average price of $44.71. The stock has a market cap of $1.88 billion and a PE ratio of 30.15.

Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings data on Friday, April 29th. The company reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.16. The company had revenue of $94.74 million for the quarter, compared to analyst estimates of $83.61 million. The company’s revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.29 EPS. On average, analysts anticipate that Cambrex Corp. will post $2.56 EPS for the current fiscal year.

In related news, Director William B. Korb sold 3,420 shares of the stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the sale, the director now owns 23,982 shares of the company’s stock, valued at approximately $1,319,010. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William B. Korb sold 8,000 shares of the stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $49.09, for a total transaction of $392,720.00. Following the sale, the director now directly owns 32,562 shares of the company’s stock, valued at approximately $1,598,468.58. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. California Public Employees Retirement System increased its stake in Cambrex Corp. by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 162,700 shares of the company’s stock worth $7,662,000 after buying an additional 800 shares during the period. GSA Capital Partners LLP increased its stake in Cambrex Corp. by 33.2% in the fourth quarter. GSA Capital Partners LLP now owns 26,475 shares of the company’s stock worth $1,247,000 after buying an additional 6,592 shares during the period. Bank of Montreal Can increased its stake in Cambrex Corp. by 31.1% in the fourth quarter. Bank of Montreal Can now owns 31,339 shares of the company’s stock worth $1,476,000 after buying an additional 7,431 shares during the period. Redwood Investments LLC increased its stake in Cambrex Corp. by 28.9% in the fourth quarter. Redwood Investments LLC now owns 45,791 shares of the company’s stock worth $2,156,000 after buying an additional 10,259 shares during the period. Finally, Stevens Capital Management LP increased its stake in Cambrex Corp. by 79.0% in the fourth quarter. Stevens Capital Management LP now owns 28,241 shares of the company’s stock worth $1,330,000 after buying an additional 12,460 shares during the period.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.